Supplemental Financial Information (Tables)

9 Months Ended

Sep. 30, 2023

Supplemental Financial Statement Information [Abstract]

Schedule of Cash, Cash Equivalents and Restricted Cash

The reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet to the totals shown within the condensed consolidated statement of cash flows is as follows (in thousands):


	As of September 30,
	2023		2022
Cash and cash equivalents	$	1,049,244	$	1,302,603
Restricted cash included in prepaid expenses and other current assets (1)	3,347		6,594
Restricted cash included in other non-current assets (1)	42,028		36,313
Total cash, cash equivalents and restricted cash	$	1,094,619	$	1,345,510

(1)Includes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement.

Schedule of Cash and Cash Equivalents


	As of September 30,
	2023		2022
Cash and cash equivalents	$	1,049,244	$	1,302,603
Restricted cash included in prepaid expenses and other current assets (1)	3,347		6,594
Restricted cash included in other non-current assets (1)	42,028		36,313
Total cash, cash equivalents and restricted cash	$	1,094,619	$	1,345,510

Summary of Property and Equipment Net

Property, plant, and equipment, net consisted of the following (in thousands):


	As of September 30,		As of December 31,
	2023		2022
Lab equipment	$	147,043	$	183,292
Leasehold improvements	83,177		125,307
Buildings and facilities	46,927		46,019
Construction in progress	15,099		23,426
Computer equipment and software	15,538		15,219
Furniture and fixtures	8,463		8,206
Land	6,060		6,060
Total property, plant, and equipment	322,307		407,529
Less: Accumulated depreciation and amortization	(120,712)		(92,756)
Property, plant, and equipment, net	$	201,595	$	314,773

Schedule of Capitalization

The following table presents the Company’s authorized, issued, and outstanding common stock as of the dates indicated (in thousands):


	Authorized	Issued	Outstanding
Common stock as of September 30, 2023:
Class A	10,500,000	1,612,729	1,497,104
Class B	4,500,000	379,141	355,621
Class C	800,000	120,000	120,000
	15,800,000	2,111,870	1,972,725
Common stock as of December 31, 2022:
Class A	10,500,000	1,448,234	1,337,499
Class B	4,500,000	383,649	354,477
Class C	800,000	200,000	200,000
	15,800,000	2,031,883	1,891,976

Schedule of Supplemental Cash Flow Information

The following table presents non-cash investing and financing activities (in thousands):


	Nine Months Ended September 30,
	2023		2022 (as adjusted)*
Supplemental disclosure of non-cash investing and financing activities:
ROU Asset obtained in exchange for new operating lease liabilities upon adoption of ASC 842	$	—	$	147,744
ROU Asset obtained in exchange for new finance lease liabilities upon adoption of ASC 842	—		3,397
ROU Asset obtained in exchange for new operating lease liabilities	13,770		75,198
ROU Asset obtained in exchange for new finance lease liabilities	—		1,370
Purchases of property and equipment included in accounts payable and accrued expenses	1,563		7,959
Equity received in related parties	—		8,873
Convertible financial instruments received for Cell Engineering services	5,595		13,689
Equity securities and warrants received for Cell Engineering services	13,843		3,423
Settlement of contingent consideration	3,222		—
Common stock issued for business and asset acquisitions	3,581		24,607
Contingent consideration for business acquisition	—		13,150
Deferred offering and acquisition costs in accounts payable and accrued expenses	—		1,660

*As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.